Browse > Article
http://dx.doi.org/10.5483/BMBRep.2021.54.8.018

MUC1-C influences cell survival in lung adenocarcinoma Calu-3 cells after SARS-CoV-2 infection  

Kim, Dongbum (Institute of Medical Science, College of Medicine, Hallym University)
Maharjan, Sony (Institute of Medical Science, College of Medicine, Hallym University)
Kim, Jinsoo (Department of Microbiology, College of Medicine, Hallym University)
Park, Sangkyu (Department of Biochemistry, College of Natural Sciences, Chungbuk National University)
Park, Jeong-A (Department of Biochemistry, College of Natural Sciences, Chungbuk National University)
Park, Byoung Kwon (Institute of Medical Science, College of Medicine, Hallym University)
Lee, Younghee (Department of Biochemistry, College of Natural Sciences, Chungbuk National University)
Kwon, Hyung-Joo (Institute of Medical Science, College of Medicine, Hallym University)
Publication Information
BMB Reports / v.54, no.8, 2021 , pp. 425-430 More about this Journal
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces coronavirus disease 2019 (COVID-19) and may increase the risk of adverse outcomes in lung cancer patients. In this study, we investigated the expression and function of mucin 1 (MUC1) after SARS-CoV-2 infection in the lung epithelial cancer cell line Calu-3. MUC1 is a major constituent of the mucus layer in the respiratory tract and contributes to pathogen defense. SARS-CoV-2 infection induced MUC1 C-terminal subunit (MUC1-C) expression in a STAT3 activation-dependent manner. Inhibition of MUC1-C signaling increased apoptosis-related protein levels and reduced proliferation-related protein levels; however, SARS-CoV-2 replication was not affected. Together, these results suggest that increased MUC1-C expression in response to SARS-CoV-2 infection may trigger the growth of lung cancer cells, and COVID-19 may be a risk factor for lung cancer patients.
Keywords
Calu-3; Lung epithelial cancer; Mucin 1; SARS-CoV-2; STAT3;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Linden SK, Sheng YH, Every AL et al (2009) MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy. PLoS Pathog 5, e1000617   DOI
2 Kandeel M, Yamamoto M, Al-Taher A et al (2020) Small molecule inhibitors of Middle East respiratory syndrome coronavirus fusion by targeting cavities on heptad repeat trimers. Biomol Ther (Seoul) 28, 311-319   DOI
3 Raina D, Ahmad R, Joshi MD et al (2009) Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 69, 5133-5141   DOI
4 Shin MJ, Kim DW, Choi YJ et al (2020) PEP-1-GLRX1 protein exhibits anti-inflammatory effects by inhibiting the activation of MAPK and NF-κB pathways in Raw 264.7 cells. BMB Rep 53, 106-111   DOI
5 Wu F, Zhao S, Yu B et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579, 265-269   DOI
6 Zhou P, Yang X, Wang X et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273   DOI
7 Nath S and Mukherjee P (2014) MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med 20, 332-342   DOI
8 Kaira K, Nakagawa K, Ohde Y et al (2012) Depolarized MUC1 expression is closely associated with hypoxic markers and poor outcome in resected non-small cell lung cancer. Int J Surg Pathol 20, 223-232   DOI
9 Li Y, Dinwiddie DL, Harrod KS, Jiang Y and Kim KC (2010) Anti-inflammatory effect of MUC1 during respiratory syncytial virus infection of lung epithelial cells in vitro. Am J Physiol Lung Cell Mol Physiol 298, L558-563   DOI
10 Banos-Lara Mdel R, Piao B and Guerrero-Plata A (2015) Differential mucin expression by respiratory syncytial virus and human metapneumovirus infection in human epithelial cells. Mediators Inflamm 2015, 347292   DOI
11 Luo J, Rizvi H, Preeshagul IR et al (2020) COVID-19 in patients with lung cancer. Ann Oncol 31, 1386-1396   DOI
12 Gao J, McConnell MJ, Yu B et al (2009) MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol 35, 337-345
13 Park BK, Maharjan S, Lee SI et al (2019) Generation and characterization of a monoclonal antibody against MERS-CoV targeting the spike protein using a synthetic peptide epitope-CpG-DNA-liposome complex. BMB Rep 52, 397-402   DOI
14 Kufe DW (2013) MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 32, 1073-1081   DOI
15 Bersanelli M (2020) Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy 12, 269-273   DOI
16 Richardson S, Hirsch JS, Narasimhan M et al (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA 323, 2052-2059   DOI
17 Yu J, Ouyang W and Chua MLK (2020) SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan. JAMA Oncol 6, 1108-1110   DOI
18 Sidaway P (2020) COVID-19 and cancer: What we know so far. Nat Rev Clin Oncol 17, 336   DOI
19 Hollingsworth MA and Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4, 45-60   DOI
20 Levitin F, Stern O, Weiss M et al (2005) The MUC1 SEA module is a self-cleaving domain. J Biol Chem 280, 33374-33386   DOI
21 Macao B, Johansson DG, Hansson GC and Hard T (2006) Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nat Struct Mol Biol 13, 71-76   DOI
22 Kufe DW (2009) Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 9, 874-885   DOI
23 Siegel RL, Miller KD and Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70, 7-30   DOI
24 Russano M, Vincenzi B, Tonini G, Tonini G and Santini D (2020) Coronavirus disease 2019 or lung cancer: What should we treat? J Thorac Oncol 15, e105-106   DOI
25 Thathiah A, Blobel CP and Carson DD (2003) Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding. J Biol Chem 278, 3386-3394   DOI
26 Zhang H, Huang Y and Xie C (2020) The treatment and outcome of a lung cancer patient infected with severe acute respiratory syndrome coronavirus-2. J Thorac Oncol 15, e63-64   DOI
27 Ahmad R, Rajabi H, Kosugi M et al (2011) MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal 4, ra9   DOI
28 Huang L, Chen D, Liu D, Yin L, Kharbanda S and Kufe D (2005) MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of betacatenin. Cancer Res 65, 10413-10422   DOI
29 Awaya H, Takeshima Y, Yamasaki M and Inai K (2004) Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol 121, 644-653   DOI
30 Park BK, Kim D, Park S et al (2021) Differential signaling and virus production in Calu-3 cells and Vero cells upon SARS-CoV-infection. Biomol Ther (Seoul) 29, 273-281   DOI
31 Thathiah A and Carson DD (2004) Mt1-Mmp mediates muc1 shedding independent of tace/adam17. Biochem J 382, 363-373   DOI
32 Kaira K, Okumura T, Nakagawa K et al (2012) MUC1 expression in pulmonary metastatic tumors: a comparison of primary lung cancer. Pathol Oncol Res 18, 439-447   DOI
33 Xu M and Wang X (2017) Critical roles of mucin-1 in sensitivity of lung cancer cells to tumor necrosis factoralpha and dexamethasone. Cell Biol Toxicol 33, 361-371   DOI
34 Lu W, Liu X, Wang T et al (2021) Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical Ill COVID-19 patients. J Med Virol 93, 582-584   DOI
35 Wu G, Kim D, Kim JN et al (2018) A mucin1 C-terminal subunit-directed monoclonal antibody targets overexpressed mucin1 in breast cancer. Theranostics 8, 78-91   DOI
36 Wu G, Maharjan S, Kim D et al (2018) A novel monoclonal antibody targets mucin1 and attenuates growth in pancreatic cancer model. Int J Mol Sci 19, 2004   DOI
37 Park BK, Kim J, Park S et al (2021) MERS-CoV and SARS-CoV-2 replication can be inhibited by targeting the interaction between the viral spike protein and the nucleocapsid protein. Theranostics 11, 3853-3867   DOI